Vertex Pharmaceuticals holds the cleaner structural position, with the lead spread across profitability and stability. Genmab A/S does not offset that deficit through any equally strong structural edge elsewhere. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (GMAB.CO: STOXX 600, VRTX: Nasdaq 100).
This is not just a one-metric split: both profitability and stability materially support the lead. The overall score gap is 38 points in favour of Vertex Pharmaceuticals Incorporated.
Both operate in: Biotechnology
This comparison is based on industry proximity, not on functional trajectory similarity. GMAB.CO and VRTX share the same industry classification.
For a similarity-based comparison, see how Genmab A/S and Vertex Pharmaceuticals each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
Score differences across key dimensions.
Left means cheaper relative valuation. Higher means stronger structure.
The setup is mixed: neither company clearly combines the stronger profile with the more supportive price setup.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where GMAB.CO and VRTX each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The profitability lead is mainly driven by a 13-point operating margin advantage.
Stability also supports the lead, so the result is broader than one isolated gap.
The lead is built on both profitability and stability, making it broader than a single-dimension result.
Break down the GMAB.CO vs VRTX comparison across all dimensions with the full interactive tool.
Explore how GMAB.CO and VRTX each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.